Nestle plans to pay US$2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its ...
REUTERS: Nestle will pay US$2 billion to buy the remaining stake in Aimmune Therapeutics Inc , gaining full ownership of the first U.S.-approved peanut allergy treatment which has struggled with a slow launch due to the COVID-19 pandemic.
The U.S. company's shares have slumped this year, as the pandemic led to many clinician's offices remaining shut, leading to a slow launch of its therapy, Palforzia, which was approved in January. "As pandemic-related disruption recedes and Palforzia's true demand begins to manifest, it will be deemed that Nestle got itself a bargain here," Raymond added.Peanut allergies are prevalent in an estimated 1.6 million teens and children in the United States alone, making it a lucrative market that could eventually help Aimmune bring in billions of dollars in sales.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Nestle to buy Aimmune Therapeutics for US$2.6 billionNestle said on Thursday it was offering US$34.50 per share for the remaining 74.4per cent in peanut allergy treatment maker Aimmune Therapeutics ...
Read more »
Nestle pays US$2 billion to secure Aimmune's allergy treatmentNestle plans to pay US$2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its ...
Read more »
Nestle pays $2 billion to secure Aimmune's allergy treatmentNestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics , as the Swiss company expands its fast-growing health science business. Known for its KitKat chocolate bars and Nescafe instant coffee, Nestle set up Nestle Health Science (NHS) in 2011 to
Read more »
Nestle pays US$2 billion to secure Aimmune's allergy treatmentNestle plans to pay US$2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its ...
Read more »
Nestle to buy Aimmune Therapeutics for US$2.6 billionNestle said on Thursday it was offering US$34.50 per share for the remaining 74.4per cent in peanut allergy treatment maker Aimmune Therapeutics ...
Read more »
Nestle pays $2 billion to secure Aimmune's allergy treatmentNestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics , as the Swiss company expands its fast-growing health science business. Known for its KitKat chocolate bars and Nescafe instant coffee, Nestle set up Nestle Health Science (NHS) in 2011 to
Read more »